vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and ONESPAWORLD HOLDINGS Ltd (OSW). Click either name above to swap in a different company.
ONESPAWORLD HOLDINGS Ltd is the larger business by last-quarter revenue ($242.1M vs $180.9M, roughly 1.3× AVANOS MEDICAL, INC.). ONESPAWORLD HOLDINGS Ltd runs the higher net margin — 5.0% vs -0.7%, a 5.7% gap on every dollar of revenue. On growth, ONESPAWORLD HOLDINGS Ltd posted the faster year-over-year revenue change (11.5% vs 0.7%). AVANOS MEDICAL, INC. produced more free cash flow last quarter ($21.3M vs $14.9M). Over the past eight quarters, ONESPAWORLD HOLDINGS Ltd's revenue compounded faster (7.1% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
AVNS vs OSW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $242.1M |
| Net Profit | $-1.3M | $12.1M |
| Gross Margin | 47.5% | — |
| Operating Margin | 1.4% | 6.8% |
| Net Margin | -0.7% | 5.0% |
| Revenue YoY | 0.7% | 11.5% |
| Net Profit YoY | 99.7% | -16.2% |
| EPS (diluted) | $-0.02 | $0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $242.1M | ||
| Q3 25 | $177.8M | $258.5M | ||
| Q2 25 | $175.0M | $240.7M | ||
| Q1 25 | $167.5M | $219.6M | ||
| Q4 24 | $179.6M | $217.2M | ||
| Q3 24 | $170.4M | $241.7M | ||
| Q2 24 | $171.7M | $224.9M | ||
| Q1 24 | $166.1M | $211.2M |
| Q4 25 | $-1.3M | $12.1M | ||
| Q3 25 | $-1.4M | $24.3M | ||
| Q2 25 | $-76.8M | $19.9M | ||
| Q1 25 | $6.6M | $15.3M | ||
| Q4 24 | $-397.3M | $14.4M | ||
| Q3 24 | $4.3M | $21.6M | ||
| Q2 24 | $1.8M | $15.8M | ||
| Q1 24 | $-900.0K | $21.2M |
| Q4 25 | 47.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 52.6% | — | ||
| Q1 25 | 53.6% | — | ||
| Q4 24 | 54.6% | — | ||
| Q3 24 | 54.5% | — | ||
| Q2 24 | 55.7% | — | ||
| Q1 24 | 57.1% | — |
| Q4 25 | 1.4% | 6.8% | ||
| Q3 25 | 0.1% | 10.2% | ||
| Q2 25 | -42.6% | 9.2% | ||
| Q1 25 | 6.1% | 7.7% | ||
| Q4 24 | -233.0% | 7.9% | ||
| Q3 24 | 7.0% | 10.3% | ||
| Q2 24 | 3.7% | 8.4% | ||
| Q1 24 | 2.4% | 8.0% |
| Q4 25 | -0.7% | 5.0% | ||
| Q3 25 | -0.8% | 9.4% | ||
| Q2 25 | -43.9% | 8.3% | ||
| Q1 25 | 3.9% | 7.0% | ||
| Q4 24 | -221.2% | 6.6% | ||
| Q3 24 | 2.5% | 8.9% | ||
| Q2 24 | 1.0% | 7.0% | ||
| Q1 24 | -0.5% | 10.0% |
| Q4 25 | $-0.02 | $0.12 | ||
| Q3 25 | $-0.03 | $0.23 | ||
| Q2 25 | $-1.66 | $0.19 | ||
| Q1 25 | $0.14 | $0.15 | ||
| Q4 24 | $-8.64 | $0.13 | ||
| Q3 24 | $0.09 | $0.20 | ||
| Q2 24 | $0.04 | $0.15 | ||
| Q1 24 | $-0.02 | $0.21 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $16.3M |
| Total DebtLower is stronger | $90.3M | $84.0M |
| Stockholders' EquityBook value | $778.2M | $542.6M |
| Total Assets | $1.1B | $707.1M |
| Debt / EquityLower = less leverage | 0.12× | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $16.3M | ||
| Q3 25 | $70.5M | $29.6M | ||
| Q2 25 | $90.3M | $35.0M | ||
| Q1 25 | $97.0M | $22.6M | ||
| Q4 24 | $107.7M | $57.4M | ||
| Q3 24 | $89.0M | $48.8M | ||
| Q2 24 | $92.2M | $62.5M | ||
| Q1 24 | $75.8M | $65.4M |
| Q4 25 | $90.3M | $84.0M | ||
| Q3 25 | $93.4M | $85.2M | ||
| Q2 25 | $95.7M | $96.2M | ||
| Q1 25 | $98.0M | $97.4M | ||
| Q4 24 | $125.3M | $98.6M | ||
| Q3 24 | $152.6M | $98.7M | ||
| Q2 24 | $164.9M | $123.8M | ||
| Q1 24 | $167.2M | $138.6M |
| Q4 25 | $778.2M | $542.6M | ||
| Q3 25 | $778.0M | $552.8M | ||
| Q2 25 | $776.3M | $548.3M | ||
| Q1 25 | $839.4M | $530.6M | ||
| Q4 24 | $828.5M | $554.5M | ||
| Q3 24 | $1.2B | $540.1M | ||
| Q2 24 | $1.2B | $532.7M | ||
| Q1 24 | $1.2B | $515.5M |
| Q4 25 | $1.1B | $707.1M | ||
| Q3 25 | $1.1B | $732.6M | ||
| Q2 25 | $1.0B | $731.8M | ||
| Q1 25 | $1.1B | $708.7M | ||
| Q4 24 | $1.2B | $746.4M | ||
| Q3 24 | $1.7B | $734.0M | ||
| Q2 24 | $1.7B | $756.8M | ||
| Q1 24 | $1.7B | $763.6M |
| Q4 25 | 0.12× | 0.15× | ||
| Q3 25 | 0.12× | 0.15× | ||
| Q2 25 | 0.12× | 0.18× | ||
| Q1 25 | 0.12× | 0.18× | ||
| Q4 24 | 0.15× | 0.18× | ||
| Q3 24 | 0.12× | 0.18× | ||
| Q2 24 | 0.13× | 0.23× | ||
| Q1 24 | 0.14× | 0.27× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $20.0M |
| Free Cash FlowOCF − Capex | $21.3M | $14.9M |
| FCF MarginFCF / Revenue | 11.8% | 6.2% |
| Capex IntensityCapex / Revenue | 3.8% | 2.1% |
| Cash ConversionOCF / Net Profit | — | 1.65× |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $68.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $20.0M | ||
| Q3 25 | $14.0M | $33.2M | ||
| Q2 25 | $6.8M | $20.3M | ||
| Q1 25 | $25.7M | $10.1M | ||
| Q4 24 | $57.9M | $16.6M | ||
| Q3 24 | $23.0M | $28.6M | ||
| Q2 24 | $27.8M | $18.7M | ||
| Q1 24 | $-8.0M | $15.0M |
| Q4 25 | $21.3M | $14.9M | ||
| Q3 25 | $7.0M | $27.6M | ||
| Q2 25 | $-4.2M | $17.6M | ||
| Q1 25 | $19.0M | $8.4M | ||
| Q4 24 | $53.1M | $13.2M | ||
| Q3 24 | $20.0M | $27.5M | ||
| Q2 24 | $21.9M | $17.6M | ||
| Q1 24 | $-12.1M | $13.7M |
| Q4 25 | 11.8% | 6.2% | ||
| Q3 25 | 3.9% | 10.7% | ||
| Q2 25 | -2.4% | 7.3% | ||
| Q1 25 | 11.3% | 3.8% | ||
| Q4 24 | 29.6% | 6.1% | ||
| Q3 24 | 11.7% | 11.4% | ||
| Q2 24 | 12.8% | 7.8% | ||
| Q1 24 | -7.3% | 6.5% |
| Q4 25 | 3.8% | 2.1% | ||
| Q3 25 | 3.9% | 2.2% | ||
| Q2 25 | 6.3% | 1.1% | ||
| Q1 25 | 4.0% | 0.8% | ||
| Q4 24 | 2.7% | 1.5% | ||
| Q3 24 | 1.8% | 0.5% | ||
| Q2 24 | 3.4% | 0.5% | ||
| Q1 24 | 2.5% | 0.6% |
| Q4 25 | — | 1.65× | ||
| Q3 25 | — | 1.36× | ||
| Q2 25 | — | 1.02× | ||
| Q1 25 | 3.89× | 0.66× | ||
| Q4 24 | — | 1.15× | ||
| Q3 24 | 5.35× | 1.33× | ||
| Q2 24 | 15.44× | 1.19× | ||
| Q1 24 | — | 0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
OSW
| Services | $197.3M | 82% |
| Products | $44.8M | 18% |
